Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05454410 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05454410 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT05454410, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant depression (TRD)
Interventions
- DRUG MIJ821 Subcutaneous Injection 1 mg
- DRUG MIJ821 Subcutaneous Injection 4 mg
- DRUG MIJ821 Subcutaneous Injection 10 mg
- DRUG Placebo Subcutaneous Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05454410
The ClinicalTrials.gov registry entry for NCT05454410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MIJ821 Subcutaneous Injection 1 mg is the first listed.
NCT05454410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05454410 about?
NCT05454410 is a clinical study titled "Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)". The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant depression (TRD)
What is the current status of trial NCT05454410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-03-13. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT05454410?
The interventions under investigation include: MIJ821 Subcutaneous Injection 1 mg (DRUG), MIJ821 Subcutaneous Injection 4 mg (DRUG), MIJ821 Subcutaneous Injection 10 mg (DRUG), Placebo Subcutaneous Injection (DRUG).
Who is sponsoring clinical trial NCT05454410?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.